TPST
NASDAQTempest Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$0.77+0.01 (+1.04%)
05:00 PM06:45 PM
News · 26 weeks57+50%
2026-04-122026-10-04
Mix3090d
- SEC Filings21(70%)
- Other5(17%)
- Leadership2(7%)
- Insider2(7%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Smith Nancy Freda4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
- INSIDERSEC Form 3 filed by new insider Smith Nancy Freda3 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
- SECSEC Form 424B3 filed by Tempest Therapeutics Inc.424B3 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form EFFECT filed by Tempest Therapeutics Inc.EFFECT - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form S-3 filed by Tempest Therapeutics Inc.S-3 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Appoints Global Finance Leader Nancy Freda-Smith to Board of DirectorsBRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that Nancy Freda-Smith has been appointed to its board of directors and will serve as Chair of the Audit Committee. "We are delighted to welcome Nancy to our board," said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. "As an experienced board director and C-suite executive who has both led and advised global Fortune 500 companies, Nancy brings deep expertise in corporate governance, global finance, e
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form DEFA14A filed by Tempest Therapeutics Inc.DEFA14A - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform-Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year -Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate is in Phase 1 dose escalation for relapsed/refractory multiple myeloma -Early clinical observations demonstrate in vivo CAR-T generation and expansion at the current highest evaluable dose, with an initial safety profile supporting continued dose escalation -Additional pipeline candidates would expand Tempest’s immune reset portfolio across hematologic malignancies and autoimmune diseases BRISBANE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NA
- PRTempest Therapeutics Announces Up to $7.5 Million Private PlacementBRISBANE, Calif. , Sept. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) (the "Company"), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,105,591 shares of common stock (or pre-funded warrant in lieu thereof), series C warrants to purchase up to 3,105,591 shares of common stock and series D warrants to purchase up to 3,105,591 shares of common stock, at a combined purchase price of $0.805 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanyin
- PRTempest to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceBRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that Matt Angel, Ph.D., Tempest’s President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. ET. The webcast will be posted to Tempest’s website at https://ir.tempesttx.com and will be archived for two weeks following the presentation. About Tempest Therapeutics Tempest is a clinical-stage biotechnology company developing next-gener
- SECSEC Form 424B3 filed by Tempest Therapeutics Inc.424B3 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form EFFECT filed by Tempest Therapeutics Inc.EFFECT - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form 8-K filed by Tempest Therapeutics Inc.8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form S-1 filed by Tempest Therapeutics Inc.S-1 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form DEFA14A filed by Tempest Therapeutics Inc.DEFA14A - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form 10-Q filed by Tempest Therapeutics Inc.10-Q - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Reports Second Quarter 2026 Financial Results and Provides Business UpdateExecuted a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027 Unveiled pipeline of next-generation in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD-7 targeted mRNA/LNP delivery approach Appointed Drake Richey and John Yee, MD, MPH, to Board of Directors BRISBANE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology compan
- SECSEC Form DEFA14A filed by Tempest Therapeutics Inc.DEFA14A - Tempest Therapeutics, Inc. (0001544227) (Filer)
TPST FAQ
6 questionsWhat does Tempest Therapeutics Inc. do?
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.Where does TPST stock trade?
Tempest Therapeutics Inc. (TPST) is listed on NASDAQ.What sector and industry is TPST in?
Tempest Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TPST?
Tempest Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1100.00 price target on 2026-01-22. Recent price targets range from $1100.00 to $1500.00.What companies are similar to TPST?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TPST side-by-side with any of them on Quantisnow.How can I track TPST on Quantisnow?
Quantisnow aggregates Tempest Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TPST to receive live email and push alerts on every new disclosure.